Correction: Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore

Correction: PharmacoEconomics – Open 10.1007/s41669-024-00507-5

In the abstract, the first sentence of the Conclusion read

“The interventions are found to be cost-effective at their existing prices when compared with BSC.”

The sentence should have read

“The interventions are not found to be cost-effective at their existing prices when compared with BSC.”

The original article has been corrected.